Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial
Lala M Dunbar, Joe Milata, Ty McClure, Margaret M Wasilewski, SIMPLIFI Study Team, Enzo Binotto, Damon Eisen, Afif Hadj, David Looke, V P Hathila, Bharat Kalambe, Rama Kant, M K Ramesh, Anthony Rozario, P P Shilotri, B Ravinder Reddy, Manjulata Anchalia, Doina Dumitrescu-Ionescu, Igor Hospodarskyy, Volodymyr Yareshko, Oleksandr Puptyuk, Antoliy Zaychuk, Ian Baird, Christopher Bunce, A C Charters, Marc Fernandez, Donald Graham, John Prestigiacomo, Luis Jauregui-Peredo, Thomas Sheftel, Arnold Luterman, Purvi Mehra, Judy Stone, Ellis Tobin, Brian Sullivan, Christian Schrock, Stanley Klein, Jose Vazquez, Paul Manos, Kleper De Almeida, Marc Alpert, Oscar De Valle, Robert Eyzaquirre, Richard C Keech, Soledad Lee, Alan E Nolasco, Vladimir Samonte, Lala M Dunbar, Joe Milata, Ty McClure, Margaret M Wasilewski, SIMPLIFI Study Team, Enzo Binotto, Damon Eisen, Afif Hadj, David Looke, V P Hathila, Bharat Kalambe, Rama Kant, M K Ramesh, Anthony Rozario, P P Shilotri, B Ravinder Reddy, Manjulata Anchalia, Doina Dumitrescu-Ionescu, Igor Hospodarskyy, Volodymyr Yareshko, Oleksandr Puptyuk, Antoliy Zaychuk, Ian Baird, Christopher Bunce, A C Charters, Marc Fernandez, Donald Graham, John Prestigiacomo, Luis Jauregui-Peredo, Thomas Sheftel, Arnold Luterman, Purvi Mehra, Judy Stone, Ellis Tobin, Brian Sullivan, Christian Schrock, Stanley Klein, Jose Vazquez, Paul Manos, Kleper De Almeida, Marc Alpert, Oscar De Valle, Robert Eyzaquirre, Richard C Keech, Soledad Lee, Alan E Nolasco, Vladimir Samonte
Abstract
Oritavancin is a novel lipoglycopeptide with demonstrated effectiveness against complicated skin and skin structure infections (cSSSI) caused by Gram-positive pathogens, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The pharmacokinetic and pharmacodynamic profile of oritavancin is favorable for single or infrequent dosing. A phase 2, multicenter, randomized, double-blind, parallel, active-comparator study (ClinicalTrials.gov identifier, NCT00514527) of single and infrequent dosing of intravenous (i.v.) oritavancin for the treatment of cSSSI caused by Gram-positive pathogens (wound infections, major abscess, and cellulitis) was undertaken to evaluate the noninferiority of front-loaded dosing regimens compared to a daily-dosing regimen. A total of 302 patients ≥ 18 years of age were randomized equally to one of three oritavancin treatment groups, receiving either a daily dose (200 mg) administered for 3 to 7 days, a single dose (1,200 mg), or an infrequent dose (800-mg dose, with the option for an additional 400 mg on day 5). The primary efficacy was defined as a clinical response in clinically evaluable (CE) patients assessed at days 21 to 29 (test of cure [TOC]). The cure rates in the CE population were 72.4% (55/76) in the daily-dose group, 81.5% (66/81) in the 1,200-mg-single-dose group, and 77.5% (55/71) in the infrequent-dose group. In patients with MRSA at baseline, the cure rates were 78.3% (18/23), 73.0% (27/37), and 87.0% (20/23) in the daily-, 1,200-mg-single-, and infrequent-dose groups, respectively; however, the study was not powered to assess outcomes in the MRSA subpopulation, and given the heterogeneity of the types of infection and the small sample size, these do not suggest any true differences in efficacy rates for these pathogens. The frequencies of adverse events were similar among treatment groups. The results of this study show that single- and infrequent-dosing schedules of oritavancin were as efficacious as daily administration and had a similar safety profile in treating cSSSI caused by Gram-positive pathogens, including MRSA.
Figures
Source: PubMed